Q5131 – Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ5131
- Long description
- Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Short description
- Inj, idacio, 20 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- Added
- July 1, 2023
- Last change
- January 1, 2025 – No change
- Termination date
- December 31, 2024
Frequently asked questions
What is HCPCS code Q5131?
Q5131 is a HCPCS Level II code for injection, adalimumab-aacf (idacio), biosimilar, 20 mg. It was discontinued on December 31, 2024.
Does Medicare cover Q5131?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q5123 – Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124 – Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5125 – Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5126 – Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
- Q5127 – Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128 – Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
- Q5129 – Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130 – Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5132 – Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg
- Q5133 – Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5134 – Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
- Q5135 – Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
- Q5136 – Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
- Q5137 – Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
- Q5138 – Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
- Q5139 – Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.